We need your support to keep TheyWorkForYou running and make sure people across the UK can continue to hold their elected representatives to account.

Donate to our crowdfunder

Haemophilia: Medical Treatments

Department of Health and Social Care written question – answered on 18th October 2018.

Alert me about debates like this

Photo of Diana R. Johnson Diana R. Johnson Labour, Kingston upon Hull North

To ask the Secretary of State for Health and Social Care, with reference to the World Federation of Haemophilia’s annual global survey, published in 2016, for what reason (a) Factor VIII and (b) Factor IX consumption per capita is lower in the UK than Ireland; and what assessment he has made of the adequacy of UK levels of factor (i) VIII and (ii) IX consumption to deliver appropriate outcomes for patients.

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary for Health and Social Care

NHS England commissions treatments for haemophilia A and haemophilia B, and other bleeding disorders, according to the current British Society for Haematology clinical guidelines. Commissioned services report outcomes via a quality dashboard. Based on the data, NHS England considers that haemophilia population outcomes are adequate, and therefore has not undertaken an assessment of the adequacy of factor levels. This will continue to be monitored as new data becomes available.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.